Core One Labs Inc. (CLABF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCore One Labs Inc. (CLABF) trades at $0.00001. Core One Labs Inc. is a biotechnology company focused on bringing psychedelic medicines to market through novel delivery systems and API grade psilocybin manufacturing. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CLABF: CLABF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLABF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CLABF: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Core One Labs Inc. (CLABF) Healthcare & Pipeline Overview
Core One Labs Inc. is a biotechnology company focused on developing novel delivery systems for psychedelic medicines and manufacturing API grade psilocybin. The company's CannaStrips technology and focus on psychedelic-assisted psychotherapy position it within the emerging market for alternative mental health treatments.
What Is the Investment Thesis for CLABF?
Core One Labs Inc. presents a speculative investment opportunity within the burgeoning psychedelic medicine market. The company's focus on novel drug delivery systems, particularly the CannaStrips technology, and its efforts in API grade psilocybin manufacturing could position it favorably within this niche. The company's negative P/E ratio of -0.28 and a significant negative profit margin of -3485.4% indicate substantial financial challenges. Ongoing: The company's ability to secure funding, navigate regulatory hurdles, and demonstrate clinical efficacy will be critical for its long-term success. Upcoming: Potential catalysts include successful clinical trials, regulatory approvals for its psychedelic medicine products, and strategic partnerships to expand its market reach.
Based on FMP financials and quantitative analysis
CLABF Key Highlights
Gross Margin of 90.8% indicates strong potential profitability on products sold, though this is offset by high operating costs.
- Negative P/E ratio of -0.28 reflects current unprofitability, suggesting the company is investing heavily in R&D and expansion.
- Market Cap of $0.00B indicates the company is a micro-cap stock with high growth potential but also significant risk.
- The company's focus on psychedelic medicines aligns with a growing market trend towards alternative mental health treatments.
- CannaStrips technology offers a novel delivery system for cannabis constituents, potentially providing a competitive advantage.
Who Are CLABF's Competitors?
CLABF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ENZN Enzon Pharmaceuticals, Inc. | $4.71 | +1.29% | $31.1M | — |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
| RPRX Royalty Pharma plc | $58.75 | -3.04% | $26.0B | 725-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CLABF's Key Strengths?
Novel CannaStrips technology for enhanced bioavailability.
- Focus on the emerging psychedelic medicine market.
- Integrated business model encompassing research, development, and clinical services.
- Expertise in API grade psilocybin manufacturing.
What Are CLABF's Weaknesses?
Negative profitability and high operating costs.
- Limited financial resources.
- Dependence on regulatory approvals for psychedelic medicines.
- Small market capitalization and limited trading volume.
What Could Drive CLABF Stock Higher?
Successful clinical trials of psychedelic medicine products.
- Regulatory approvals for psychedelic medicine products in key markets.
- Expansion of clinic operations and service offerings.
- Strategic partnerships with pharmaceutical companies and research institutions.
- Scaling up API grade psilocybin manufacturing capacity.
What Are the Key Risks for CLABF?
Financial-distress signal — its Altman Z-Score of -34.18 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing regulations for psychedelic medicines.
- Competition from established pharmaceutical companies and other biotech firms.
- Adverse clinical trial results.
- Difficulty securing funding and attracting investors.
- Limited financial disclosure and transparency as an OTC stock.
What Are the Growth Opportunities for CLABF?
- Expansion of Psychedelic-Assisted Psychotherapy Services: Core One Labs can capitalize on the growing acceptance of psychedelic-assisted psychotherapy by expanding its clinic operations and developing standardized treatment protocols. The market for mental health services is substantial, with a global market size estimated at hundreds of billions of dollars. Timeline: Ongoing, with continuous expansion of clinic networks and service offerings.
- Development and Commercialization of Novel Drug Delivery Systems: The CannaStrips technology and other novel delivery systems offer a unique value proposition for both cannabis and psychedelic compounds. Timeline: Ongoing, with continuous research and development efforts to optimize delivery methods.
- API Grade Psilocybin Manufacturing: Establishing a reliable and scalable API grade psilocybin manufacturing capability can position Core One Labs as a key supplier to the research and clinical market. The demand for high-quality psilocybin is expected to increase as research and clinical trials expand. Timeline: Upcoming, with ongoing efforts to scale up production capacity.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with pharmaceutical companies, research institutions, and other industry players can accelerate the development and commercialization of Core One Labs' products and services. Acquisitions of complementary technologies or businesses can expand the company's capabilities and market reach. Timeline: Ongoing, with continuous exploration of potential partnerships and acquisition opportunities.
- Geographic Expansion into New Markets: Expanding operations into new geographic markets, particularly in regions with favorable regulatory environments for psychedelic medicines, can drive significant growth. The global market for psychedelic medicines is expected to expand rapidly as regulations evolve. Timeline: Upcoming, with planned expansion into key markets in North America and Europe.
What Are CLABF's Competitive Advantages?
- Proprietary CannaStrips technology for enhanced bioavailability.
- Expertise in API grade psilocybin manufacturing.
- Early mover advantage in the emerging psychedelic medicine market.
- Integrated business model encompassing research, development, manufacturing, and clinical services.
What Does CLABF Do?
Core One Labs Inc., established in 2010 and headquartered in Vancouver, Canada, operates as a biotechnology research and technology life sciences company. Originally named Lifestyle Delivery Systems Inc., the company rebranded in September 2019 to reflect its evolving focus. Core One Labs is dedicated to bringing psychedelic medicines to market through innovative delivery systems, psychedelic-assisted psychotherapy, and the manufacturing of API grade psilocybin. A key technology is CannaStrips, infused strips designed to enhance the bioavailability of cannabis constituents. Beyond its core research and development, Core One Labs offers consulting, financing, and micro cultivation services. The company also operates medical and wellness clinics, providing natural health products and news dissemination services. Core One Labs aims to be a leader in the emerging psychedelic medicine market, addressing unmet needs in mental health treatment through its diverse range of products and services.
What Products and Services Does CLABF Offer?
- Develop novel delivery systems for psychedelic medicines
- Manufacture API grade psilocybin
- Offer psychedelic-assisted psychotherapy
- Produce CannaStrips for enhanced bioavailability of cannabis constituents
- Provide consulting, financing, and micro cultivation services
- Operate medical and wellness clinics
- Offer natural health products
- Provide news dissemination services
How Does CLABF Make Money?
- Revenue from the sale of CannaStrips and other cannabis-infused products.
- Fees from consulting, financing, and micro cultivation services.
- Revenue from medical and wellness clinic operations.
- Potential future revenue from the sale of API grade psilocybin and psychedelic medicines.
What Industry Does CLABF Operate In?
Core One Labs Inc. operates within the rapidly evolving biotechnology sector, specifically targeting the emerging market for psychedelic medicines. This market is driven by increasing acceptance of alternative mental health treatments and growing research into the therapeutic potential of psychedelics. The competitive landscape includes companies like CNGGF (CLS Holdings USA, Inc.), CTABF (Canna-Global Acquisition Corp.), DOSEF (Mindset Pharma Inc.), ENZN (Enzon Pharmaceuticals, Inc.), and FNAM (Fanam Holding Corp.), all vying for market share. The industry faces regulatory hurdles and requires significant investment in research and development.
Who Are CLABF's Key Customers?
- Patients seeking alternative mental health treatments.
- Cannabis consumers looking for innovative delivery methods.
- Research institutions and pharmaceutical companies requiring API grade psilocybin.
- Businesses in the cannabis and psychedelic industries seeking consulting and financing services.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 51 |
| 2026-08-26 | 51 |
| 2026-08-29 | 51 |
| 2026-09-01 | 51 |
| 2026-09-04 | 51 |
| 2026-09-07 | 51 |
| 2026-09-10 | 51 |
What changed?
The score has stayed at 51.
Over the same 18 days the stock moved +0.0%.
Company Profile
Core One Labs Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Gareth Manderson. CLABF has traded publicly since 2015.
Key Financial Metrics
Its free cash flow yield is -29.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.81 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Core One Labs Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -34.18 places it in the distress zone, a signal of elevated financial risk.
CLABF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel CannaStrips technology for enhanced bioavailability.
- Focus on the emerging psychedelic medicine market.
- Integrated business model encompassing research, development, and clinical services.
- Expertise in API grade psilocybin manufacturing.
Bear Case
- Negative profitability and high operating costs.
- Limited financial resources.
- Dependence on regulatory approvals for psychedelic medicines.
- Small market capitalization and limited trading volume.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CLABF Latest News
-
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
benzinga · Jul 24, 2023
-
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
· Oct 18, 2021
-
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
· Oct 13, 2021
-
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
· May 10, 2021
CLABF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CLABF.
Price Targets
Wall Street price target analysis for CLABF.
CLABF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CLABF; grades run from A+ (80-100) to F (below 30).
Latest News
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
Leadership: Joel Shacker
CEO
Joel Shacker is the Chief Executive Officer of Core One Labs Inc. His background includes experience in the biotechnology and life sciences sectors. He has been involved in various aspects of company management, including strategic planning, business development, and financial oversight. Shacker's expertise lies in guiding companies through growth phases and navigating the complexities of the healthcare industry.
Track Record: Under Joel Shacker's leadership, Core One Labs Inc. has focused on developing novel delivery systems for psychedelic medicines and establishing API grade psilocybin manufacturing capabilities. Key milestones include the development of the CannaStrips technology and the expansion of the company's research and development efforts in the psychedelic medicine space. The company has also worked to establish strategic partnerships and expand its clinic operations.
CLABF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Core One Labs Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has a physical headquarters and operational facilities.
- Management team has relevant experience in the biotechnology and pharmaceutical industries.
- Company has patents or trademarks for its technologies.
- Company has partnerships with reputable research institutions or pharmaceutical companies.
Common Questions About CLABF (Healthcare)
Is CLABF a good stock?
Stock Expert AI does not rate CLABF buy, sell or hold. Core One Labs Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CLABF stock?
Generally, micro-cap OTC stocks like Core One Labs Inc. are not widely covered by analysts due to their small market capitalization and limited trading volume.
What are the key factors to evaluate for CLABF?
Evaluate CLABF on fundamentals, analyst consensus, and risk factors. Gross Margin of 90.8% indicates strong potential profitability on products sold, though this is offset by high operating costs. Not financial advice.
How frequently does CLABF data refresh on this page?
CLABF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CLABF's recent stock price performance?
Core One Labs Inc. (CLABF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel CannaStrips technology for enhanced bioavailability. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLABF overvalued or undervalued right now?
Core One Labs Inc. (CLABF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CLABF?
Yes, most major brokerages offer fractional shares of Core One Labs Inc. (CLABF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CLABF's earnings and financial reports?
Core One Labs Inc. (CLABF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CLABF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company information and may be limited due to the company's OTC status.